FDAsafety guidance66% confidence
Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Sun Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Immunology · IL-23
- Sub-indication
- Ild
Related signal: FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma